Integration of Bioinformatics Analysis Reveals ZNF248 As a Potential Prognostic and Immunotherapeutic Biomarker for LIHC: Machine Learning and Experimental Evidence

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2024 Dec 11

PMID 39659932

Authors

Lifang Weng

Zhicheng Cheng

Zhisong Qiu

Jin Shi

Libin Chen

Chunsheng He

Lijuan Wang

Feng Jin

Affiliations

Soon will be listed here.

Abstract

Liver hepatocellular carcinoma (LIHC) is a major contributor to cancer-related mortality worldwide, posing substantial diagnostic and therapeutic challenges. Although zinc finger proteins (ZNFs) are known to play a role in LIHC, the specific function of ZNF248 remains poorly understood. In this study, we analyzed genomic and clinical data from The Cancer Genome Atlas (TCGA) to elucidate the role of ZNF248 through differential expression analysis, bioenrichment, immune response correlation, and drug sensitivity evaluation. Machine learning was employed to identify prognostic signatures derived from ZNF248, which were further validated using Receiver Operating Characteristic (ROC) analysis. Functional assays, including Western blot and rescue experiments, were performed to assess the impact of ZNF248 on the PI3K/AKT signaling pathway. Our results demonstrate that ZNF248 is significantly overexpressed in LIHC patients and is associated with poor prognosis. Bioenrichment analysis revealed activation of oncogenic pathways, and elevated ZNF248 expression correlated with increased immune cell infiltration and enhanced immune scores, thereby influencing both immunotherapy response and drug sensitivity. Functional assays further confirmed that ZNF248 promotes LIHC progression and invasion, while silencing ZNF248 inhibited the PI3K/AKT pathway - a phenomenon reversible by the AKT activator SC79. These findings suggest that ZNF248 contributes to LIHC progression through the PI3K/AKT pathway and may represent a novel immunotherapeutic target and prognostic biomarker for LIHC.

References

Lu H, Wu J, Liang L, Wang X, Cai H . Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Signature Contributes to Predicting Prognosis and Tumor Microenvironment of Bladder Cancer. Front Immunol. 2022; 13:803355. PMC: 8828980. DOI: 10.3389/fimmu.2022.803355. View

Balachandran V, Gonen M, Smith J, DeMatteo R . Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015; 16(4):e173-80. PMC: 4465353. DOI: 10.1016/S1470-2045(14)71116-7. View

Uzbekov R, Prigent C . A Journey through Time on the Discovery of Cell Cycle Regulation. Cells. 2022; 11(4). PMC: 8870340. DOI: 10.3390/cells11040704. View

Palmeri M, Mehnert J, Silk A, Jabbour S, Ganesan S, Popli P . Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers. ESMO Open. 2021; 7(1):100336. PMC: 8717431. DOI: 10.1016/j.esmoop.2021.100336. View

Xie W, Qiao X, Shang L, Dou J, Yang X, Qiao S . Knockdown of ZNF233 suppresses hepatocellular carcinoma cell proliferation and tumorigenesis. Gene. 2018; 679:179-185. DOI: 10.1016/j.gene.2018.08.070. View

Racle J, Gfeller D . EPIC: A Tool to Estimate the Proportions of Different Cell Types from Bulk Gene Expression Data. Methods Mol Biol. 2020; 2120:233-248. DOI: 10.1007/978-1-0716-0327-7_17. View

Fang T, Lv H, Lv G, Li T, Wang C, Han Q . Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nat Commun. 2018; 9(1):191. PMC: 5768693. DOI: 10.1038/s41467-017-02583-0. View

Lee Y, Chuah S, Nguyen P, Lim C, Lai H, Wasser M . IFNγIL-17 CD8 T cells contribute to immunosuppression and tumor progression in human hepatocellular carcinoma. Cancer Lett. 2022; 552:215977. DOI: 10.1016/j.canlet.2022.215977. View

Wang T, Dai L, Shen S, Yang Y, Yang M, Yang X . Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm. Front Immunol. 2022; 13:843408. PMC: 9186446. DOI: 10.3389/fimmu.2022.843408. View

10.

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

11.

Yan C, Niu Y, Ma L, Tian L, Ma J . System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma. J Transl Med. 2022; 20(1):452. PMC: 9531858. DOI: 10.1186/s12967-022-03630-1. View

12.

Chen B, Khodadoust M, Liu C, Newman A, Alizadeh A . Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Methods Mol Biol. 2018; 1711:243-259. PMC: 5895181. DOI: 10.1007/978-1-4939-7493-1_12. View

13.

Guy J, Hearn T, Crosier M, Mudge J, Viggiano L, Koczan D . Genomic sequence and transcriptional profile of the boundary between pericentromeric satellites and genes on human chromosome arm 10p. Genome Res. 2003; 13(2):159-72. PMC: 420363. DOI: 10.1101/gr.644503. View

14.

Shukla R, Upton K, Munoz-Lopez M, Gerhardt D, Fisher M, Nguyen T . Endogenous retrotransposition activates oncogenic pathways in hepatocellular carcinoma. Cell. 2013; 153(1):101-11. PMC: 3898742. DOI: 10.1016/j.cell.2013.02.032. View

15.

Zuo Z . Quantifying the arms race between LINE-1 and KRAB-zinc finger genes through TECookbook. NAR Genom Bioinform. 2023; 5(3):lqad078. PMC: 10480687. DOI: 10.1093/nargab/lqad078. View

16.

Malta T, Sokolov A, Gentles A, Burzykowski T, Poisson L, Weinstein J . Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell. 2018; 173(2):338-354.e15. PMC: 5902191. DOI: 10.1016/j.cell.2018.03.034. View

17.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

18.

Donne R, Lujambio A . The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology. 2022; 77(5):1773-1796. PMC: 9941399. DOI: 10.1002/hep.32740. View

19.

Forner A, Reig M, Bruix J . Hepatocellular carcinoma. Lancet. 2018; 391(10127):1301-1314. DOI: 10.1016/S0140-6736(18)30010-2. View

20.

Li K, Luo H, Huang L, Luo H, Zhu X . Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int. 2020; 20:16. PMC: 6958913. DOI: 10.1186/s12935-019-1091-8. View